Overview of Dentinox Teething(ANESTETICS)

Property	Description
Active Ingredient	Lidocaine Hydrochloride
Form	Oral Solution (Liquid Preparation)
Pharmacological Class	Local Anesthetic Agent
Common Use	Symptomatic relief of teething pain
Origin	Synthetic (Amide-type)

What Type of Medicinal Product is Dentinox Teething Solution?

Dentinox Teething Solution is a recognized medicinal product intended for the temporary relief of localized oral discomfort in infants and babies, specifically designed for oromucosal application. It is formally classified as a Local Anesthetic Agent—a class of drugs defined by their action of reversibly blocking nerve conduction when applied topically. This classification confirms that its effect is concentrated only at the site of application, distinguishing it from general oral analgesic medications. The product is presented as an Oral Solution (a liquid pharmaceutical preparation), a dosage form often favored for ease of use on a baby's gums.

Composition and Unique Formulation Features

The primary component responsible for the therapeutic effect is Lidocaine Hydrochloride. Lidocaine is a synthetic compound and is the characteristic example of the amide class anesthetics. This solution is prepared using an Aqueous/Hydroalcoholic Solution as its vehicle and is a single active ingredient product. The specific formulation is clinically recognized for providing symptomatic relief and serves as an accessible, over-the-counter option for managing discomfort related to infant teething.

General Purpose and Action for Teething Pain

The general purpose of the solution is to provide a focused, localized analgesic effect for the symptomatic treatment of pain associated with infant teething. As a Local Anesthetic Agent, the active ingredient works directly on the sensory nerve endings in the gum tissue, temporarily preventing the transmission of pain signals to the brain. This mechanism ensures that the resulting relief is targeted and temporary, directly addressing the soreness at its source, and confirming its role as a non-systemic intervention for short-term pain management.

Regulatory References

Local Anesthesia - MedlinePlus

What side effects are possible with Dentinox Teething(ANESTETICS)?

Possible Side Effects and Safety Information

This section outlines the possible adverse reactions and official safety characteristics of products containing Lidocaine Hydrochloride, the active ingredient in Dentinox Teething Solution, as classified in government regulatory documents.

Adverse Reaction Scope

Category	Documented Official Adverse Reactions
Local/Expected Effects	Temporary burning or stinging sensation at the application site, local numbness extending beyond the immediate area, and taste disturbances.
Hypersensitivity	Reactions categorized under Immune System Disorders, including rash and hives. The most serious documented reaction of this type is anaphylaxis (anaphylactic shock).

Systemic and Serious Safety Concerns

The primary serious safety concern is Systemic Toxicity, which may occur from excessive application or rapid absorption. Systemic effects are typically categorized as Rare or Very Rare in regulatory documentation but require specific attention in the pediatric population.

These reactions relate to the Nervous System Disorders and Cardiac Disorders and include symptoms such as central nervous system excitation (agitation, dizziness) and, in severe cases, seizures, respiratory depression, bradycardia (slow heart rate), and hypotension (low blood pressure).

Population-Specific Safety Notes

Official health authorities, including the MHRA and FDA, have issued specific warnings concerning the use of oral lidocaine products for infant teething. These warnings underscore a heightened risk of Systemic Toxicity in the pediatric population compared to adults due to the increased potential for systemic exposure and accumulation in young children.

Safety labeling also defines that the medicine is formally contraindicated in individuals with a known history of hypersensitivity to the amide-type local anesthetic class.

Overdose and Emergency Response

Overdose Manifestations

The overdose profile for this product is defined by the potential for systemic toxicity from the active ingredient, Lidocaine Hydrochloride. Overdose manifests as a progression of Central Nervous System (CNS) effects. Initial signs of elevated plasma concentrations may include drowsiness, dizziness, confusion, tinnitus (ringing in the ears), or muscle twitching.

Severe Outcomes and Specific Risks

This toxicity can escalate to severe, life-threatening outcomes. Officially documented manifestations include generalized convulsions, followed by unconsciousness, and the potential for respiratory arrest and cardiovascular collapse, including cardiac arrest. A distinct, documented risk involves the hematological disorder methemoglobinemia, which presents as cyanosis (pale, gray, or blue discoloration of the skin, lips, or nail beds). This complication is noted as a particular concern in infants under 6 months of age.

Mandated Emergency Actions

The regulatory requirement is to seek immediate medical attention for any signs of severe systemic toxicity, such as lethargy, shallow breathing, or seizure activity. Likewise, immediate medical help must be sought right away if signs of cyanosis are observed. Treatment for systemic toxicity is primarily symptomatic and supportive, as no specific antidote is known for general lidocaine overdose.

Therapeutic Uses of Dentinox Teething(ANESTETICS)

Dentinox Teething Solution is a localized treatment relevant in contexts marked by increased discomfort or tension, specifically associated with the normal process of infant teething. It is generally applied across conditions characterized by periods of episodic or fluctuating manifestations of oral pain in babies. This type of product is considered relevant when supportive symptom management is appropriate, particularly when non-medicinal options have failed to provide necessary relief.

The solution is applied in addressing symptom clusters that may become intense or disruptive, such as localized pain, soreness, and tenderness of the gum tissue, and the secondary fussiness that often interferes with feeding or sleep. The use of this topical agent provides support that helps ease the overall symptom burden.

Supporting Comfort During Periods of Distress

This medication is considered relevant in contexts marked by increased discomfort or tension, addressing symptom clusters that may become intense or disruptive. By managing the primary oral discomfort, the treatment contributes to improved day-to-day comfort during symptomatic periods. This supports general well-being during symptomatic phases and contributes to easing the overall symptom load.

Symptomatic Focus: Relief for Localized Oral Pain

This solution provides supportive relief when symptoms interfere with routine activities, and is commonly used for managing acute pain associated with primary tooth eruption in infants.

Regulatory References

UK Medicines and Healthcare products Regulatory Agency (MHRA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Dentinox Teething (Anesthetics)?

The eligibility profile for this lidocaine-containing product is strictly defined by regulatory authorities and is determined by age, allergies, and specific underlying conditions.

Eligible Population and Age Rules

The medicine is authorized for use in babies and children from 5 months of age for the symptomatic relief of teething discomfort. Use is not established for adolescents, adults, or older adults, as the indication is restricted solely to infants experiencing teething. Eligibility status is not applicable for pregnant or breastfeeding individuals, as the product is intended exclusively for pediatric use.

Absolute Contraindications

Dentinox Teething Solution must not be used in the following populations:

Infants under 5 months old.
Individuals with a known allergy or hypersensitivity to lidocaine or to any other local anesthetics of the amide-type.
Patients diagnosed with hereditary fructose intolerance due to the presence of an excipient (sorbitol) in the formulation.

Population Restrictions

Use is conditional and requires caution in babies who have significant injuries or damaged mucosa in the mouth. Furthermore, regulatory agencies prohibit the use of high-concentration oral viscous lidocaine for teething pain in infants, marking a critical population restriction based on product concentration and region.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for this topical local anesthetic formulation focuses on exposure-related restrictions and population-specific risk, rather than complex metabolic drug-drug interactions.

Pharmacodynamic and Exposure Interactions

The primary interaction involves additive systemic exposure when co-administered with other products from the same pharmacological class. The toxic effects of local anesthetic agents, such as Lidocaine, are additive. Therefore, a mandatory restriction requires that this medicine must not be used at the same time as any other products that contain lidocaine. This rule directly addresses the risk of excessive systemic plasma levels from cumulative doses.

Administration-Timing Interactions

The product's use in the mouth necessitates a timing constraint related to ingestion. Because the local anesthetic effect produces oral numbness, which may impair swallowing, official regulatory information advises a period of separation from food intake. This prevents the potential danger of aspiration or biting trauma while the tissue is anesthetized.

Population-Specific Restrictions

Specific regulatory caution exists regarding the use of oral lidocaine solutions for teething pain in infants and young children. The U.S. Food and Drug Administration (FDA) has restricted the use of similar viscous solutions due to the documented risk of severe systemic toxicity, including seizures and cardiopulmonary events, resulting from potentially high plasma levels in this vulnerable population.

Mechanism of Action

The function of the anesthetic component, Lidocaine, is determined by its ability to reversibly interrupt electrical signal flow in peripheral nerve endings, ensuring the effect is rapid and strictly localized.

Blockade of Voltage-Gated Sodium Channels ( Na V)

The core mechanism involves the inhibition of voltage-gated sodium channels ( Na V) located on the peripheral sensory nerve membranes. The molecule physically obstructs the channel pore from the cell's interior, preferentially binding during the channel's inactivated state (use-dependent block), which directly targets the electrical component of nerve function. This action limits the nerve's ability to undergo the rapid depolarization necessary to propagate an impulse.

Reversible Interruption of Peripheral Signal Transmission

This molecular blockade results in the cessation of action potential conduction along the sensory nerve fibers of the oral mucosa. This interruption of the nociceptive signaling pathway prevents the transmission of afferent electrical signals. The resulting physiological effect is localized suppression of sensory nerve conduction (loss of electrical excitability), which is temporary because the effect persists only until the molecule diffuses away from the channels and is washed out of the local tissue.

Dosage and Administration Information

Instruction Map: How to use Dentinox Teething (ANESTETICS)

This map summarizes the instructions for the use of Lidocaine Hydrochloride (Dentinox Teething products).

Administration Scope

Instruction Domain	Guidelines
Route of administration:	Oromucosal (Topical application to the mucous membrane of the mouth).
Dosing schedule:	A pea-sized amount of the product, which is approximately 0.2 grams of the gel formulation.
Timing in relation to meals (if applicable):	Not specified; the dose interval is based on the 3-hour minimum and 6 doses per 24 hours maximum.
Preparation requirements (if applicable):	No preparation steps (e.g., dilution or reconstitution) are required.
Age-group administration rules:	For use in children from 5 months of age and older.
Missed-dose rules:	The minimum 3-hour interval must be observed between applications, even if a previous dose was vomited or spat out.
Special procedural conditions:	Must be used only when non-pharmacological treatments have failed to provide relief. Do not use more than one Lidocaine-containing product concurrently.

Instruction Classifications (High-Level)

Classification	Description
Administration method type:	Topical (Localized application).
Frequency pattern:	As-needed (Intermittent use), restricted by a minimum 3-hour interval.
Use-context constraints:	Second-line intervention and restricted to supply under the supervision of a pharmacist.

Resulting Procedural Structure

Step sequence:

Apply a pea-sized amount of the product (approx. 0.2 grams) directly onto the sore gum area using a clean fingertip.
Wait a minimum of 3 hours before applying the next dose, if necessary.
The total number of applications must not exceed 6 doses within a 24-hour window.
Discontinue use if symptoms resolve or if the total treatment duration exceeds 7 days.

Connection to the overall use protocol: The protocol establishes a structured, short-term approach for administration, controlling the unit dose volume, the minimum interval between applications, and the maximum 24-hour exposure. This governs the product's use as an intermittent, second-line, oromucosal application, defining the boundaries for frequency and total course duration.

Recent Clinical Evidence

Recent Clinical Evidence and Regulatory Stance

Dentinox Teething Gel contains the active ingredients lidocaine hydrochloride (a local anesthetic) and cetylpyridinium chloride (an antiseptic). The gel is formulated for the relief of pain and discomfort associated with teething.

Efficacy and Safety Concerns

High-quality clinical evidence supporting the efficacy of topical anesthetic gels, particularly those containing lidocaine, for managing teething discomfort is limited and often difficult to interpret due to study design flaws. Some systematic reviews have concluded that definitive conclusions on their effectiveness cannot be drawn due to the very low certainty of evidence.

Safety Profile: Regulatory bodies and major pediatric professional organizations have issued warnings or do not recommend the use of topical anesthetics like lidocaine for teething pain in infants and young children. The US Food and Drug Administration (FDA), for instance, has required the strongest warning (a Boxed Warning) on prescription viscous lidocaine solution, which is sometimes misused for this purpose, due to concerns over toxicity when excessive amounts are applied or accidentally ingested.
Risk Reporting: Case reports have documented serious adverse events of varying severity, including seizures, respiratory distress, and cardiac issues, associated with the use of lidocaine-based teething gels when administered incorrectly or in excess to infants.

Alternative Therapies in Research

Recent research has explored alternatives to topical anesthetics. Some studies have investigated gels containing high-molecular-weight hyaluronic acid (HMWHA), which functions as a medical device to create a protective barrier on the gum tissue. Preliminary studies comparing HMWHA to local anesthetic gels have suggested that these newer formulations may be effective in improving teething symptoms like pain, swelling, and redness, often exhibiting a favorable tolerability profile.

Frequently Asked Questions (FAQ)

Common questions about Dentinox Teething(ANESTETICS) (FAQ)

Q: How quickly does Dentinox Teething(ANESTETICS) typically start to work?

The active ingredient in this product is a local anesthetic, which is a type of medicine designed to have a rapid and localized effect by reversibly blocking nerve conduction at the site of application. Official administration guidelines indicate that a second application, if needed, can be given after a minimum of 3 hours.

Q: How long does the effect of Dentinox Teething(ANESTETICS) usually last?

The effect is localized and temporary, working only at the site of application. The official administration schedule requires that a minimum of 3 hours must pass between applications if relief is still needed, which defines the boundary for the product's intended intermittent use.

Q: Can Dentinox Teething(ANESTETICS) be used alongside paracetamol or ibuprofen?

The official product information specifically warns that this medicine must not be used at the same time as any other products that contain the same active ingredient, lidocaine, to avoid excessive exposure. Official regulatory documents do not specify warnings or contraindications related to co-administration with paracetamol or ibuprofen.

Q: Are there any common allergens in Dentinox Teething(ANESTETICS)?

Official information states that the product should not be used by individuals with a known allergy or hypersensitivity to lidocaine, cetylpyridinium, or any of the product's excipients (non-active ingredients). The complete list of ingredients is detailed in the official product information.

Q: What happens if Dentinox Teething(ANESTETICS) is used too frequently?

The administration is strictly limited to a maximum of six doses in any 24-hour period. Exceeding the recommended dosage and frequency increases the potential for systemic exposure to the active ingredient, which is associated with a heightened risk of serious adverse events in infants, according to official warnings.

Q: Are there any warnings about using Dentinox Teething(ANESTETICS) with certain medical conditions?

Yes, official warnings advise that the product is formally contraindicated in patients diagnosed with hereditary fructose intolerance because it contains the excipient sorbitol. Caution is also noted for use in babies who have significant injuries or damaged mucosa (the lining) in the mouth.

Q: Is Dentinox Teething(ANESTETICS) the same as other teething gels?

Dentinox Teething Gel is defined by its active ingredients: lidocaine hydrochloride (a local anesthetic) and cetylpyridinium chloride (an antiseptic). Other teething gels may contain different active components, such as herbal extracts or other anesthetic agents.

Q: Does Dentinox Teething(ANESTETICS) contain sugar?

According to the official product information, this product is formulated to be sugar-free. It uses alternative sweeteners such as xylitol and sorbitol.

Q: What is the consistency of Dentinox Teething(ANESTETICS) gel?

Official documentation describes its appearance as a greenish-yellow-brown dental gel, which is a semi-solid preparation for oromucosal application.

Q: What is the difference between Dentinox Teething(ANESTETICS) and teething powders?

Dentinox Teething Gel is a semi-solid preparation intended for topical application to the gums (oromucosal use). This pharmaceutical form and its localized application method distinguish it from teething powders, which are dry solid dosage forms.

Q: Does Dentinox Teething(ANESTETICS) contain alcohol?

Yes, the formulation contains a small amount of ethanol (alcohol), which is listed as an excipient (non-active ingredient). Official patient information indicates that the amount of ethanol is described as less than 100 mg per dose.

Q: Is Dentinox Teething(ANESTETICS) classified as an over-the-counter medicine?

Regulatory guidance in certain jurisdictions specifies that products containing lidocaine for teething are to be supplied in a pharmacy under the supervision of a pharmacist.

Q: Are there different formulas or strengths of Dentinox Teething(ANESTETICS)?

The primary formulation for this product is defined by a specific concentration: 0.33% w/w lidocaine hydrochloride and 0.10% w/w cetylpyridinium chloride in a dental gel.

Q: Can Dentinox Teething(ANESTETICS) be used for adult mouth ulcers?

The medicine is formally authorized only for the symptomatic relief of pain and discomfort associated with teething in children from 5 months of age. Use in adults or for conditions other than teething is not within the authorized therapeutic indications.

Q: Does Dentinox Teething(ANESTETICS) contain benzocaine or lidocaine?

The active anesthetic ingredient in this product is lidocaine hydrochloride. Benzocaine is not listed as an active ingredient in this formulation.

Q: What is the expected shelf life or expiry after opening Dentinox Teething(ANESTETICS)?

Official product information states that the shelf life after the first opening of the tube is 1 year. Regardless of when it was opened, the product must always be discarded if it reaches the printed expiry date on the packaging.

Q: Can Dentinox Teething(ANESTETICS) be used with other topical oral products?

Regulatory information specifically warns that the medicine must not be used at the same time as any other products that contain lidocaine. This restriction is associated with the need to avoid the risk of additive systemic exposure.

Q: What is the purpose of the non-active ingredients in Dentinox Teething(ANESTETICS)?

The non-active ingredients (excipients) fulfill various roles, such as forming the gel structure, providing sweetness (e.g., Xylitol and Sorbitol), or acting as a preservative.

Q: Can Dentinox Teething(ANESTETICS) be applied directly to a dummy or pacifier?

The official administration instructions describe the product being applied directly to the sore gum area using a 'clean fingertip' or a cotton pad. The use of a dummy or pacifier as an application method is not described in the official regulatory procedure.

Q: Is Dentinox Teething(ANESTETICS) recommended for night-time use?

The therapeutic indication is for symptomatic relief of pain and discomfort associated with teething. Its use is governed by a minimum 3-hour interval between doses and a maximum of six doses in 24 hours.

Q: Does Dentinox Teething(ANESTETICS) need to be stored in the refrigerator?

The official storage instructions require that the product must not be stored above 25 C. The instructions do not require or suggest that the product should be stored in the refrigerator.

Q: Can Dentinox Teething(ANESTETICS) cause irritation outside the mouth?

The known local adverse effects listed in the official safety information are described as temporary burning or stinging sensation at the application site on the oral mucosa (the gums). Irritation in other areas is not a specific local adverse effect documented in the official product information.

Q: Is it important to wash hands before and after applying Dentinox Teething(ANESTETICS)?

The official administration method specifies using a 'clean fingertip,' which emphasizes the need for hygiene during application.

How should Dentinox Teething(ANESTETICS) be stored and disposed of?

How to Store and Dispose of Dentinox Teething Solution

The storage and disposal of Dentinox Teething Solution are governed by official regulatory instructions to ensure product stability and safety.

Storage Conditions

The medicinal product must not be stored above 25 C to maintain its quality and potency. The solution must be stored in its original container and the bottle should be kept tightly closed when not in use. As a mandatory safety requirement, the medicine must be kept out of the sight and reach of children at all times. The solution should not be used past the expiry date printed on the packaging.

Disposal Instructions

Unused or expired Dentinox Teething Solution must not be disposed of in household waste or wastewater (e.g., sink or toilet). For proper environmental protection, any unused medicine must be returned to a pharmacist who will ensure its disposal according to official pharmaceutical waste guidelines.

Dentinox Teething(ANESTETICS)